Cargando…

Does Aggressive Surgery Mean Worse Quality of Life and Functional Capacity in Retroperitoneal Sarcoma Patients?—A Retrospective Study of 161 Patients from China

SIMPLE SUMMARY: The mainstay of treatment for primary retroperitoneal sarcoma is surgery. In this study, we found that aggressive surgery did not imply a poorer quality of life and functional capacity compared to a surgical strategy of simple tumor resection. This has implications for patient consul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Aobo, Fang, Yuan, Ma, Lijie, Yang, Hua, Lu, Weiqi, Zhou, Yuhong, Zhang, Yong, Tong, Hanxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600768/
https://www.ncbi.nlm.nih.gov/pubmed/36291911
http://dx.doi.org/10.3390/cancers14205126
_version_ 1784816925565517824
author Zhuang, Aobo
Fang, Yuan
Ma, Lijie
Yang, Hua
Lu, Weiqi
Zhou, Yuhong
Zhang, Yong
Tong, Hanxing
author_facet Zhuang, Aobo
Fang, Yuan
Ma, Lijie
Yang, Hua
Lu, Weiqi
Zhou, Yuhong
Zhang, Yong
Tong, Hanxing
author_sort Zhuang, Aobo
collection PubMed
description SIMPLE SUMMARY: The mainstay of treatment for primary retroperitoneal sarcoma is surgery. In this study, we found that aggressive surgery did not imply a poorer quality of life and functional capacity compared to a surgical strategy of simple tumor resection. This has implications for patient consultation in daily practice, the clinical decision-making of surgeons, and even for subsequent prospective clinical studies on the quality of life. ABSTRACT: The mainstay of treatment for primary retroperitoneal sarcoma (RPS) is surgery. However, whether multiple visceral resection (MVR) affects patients’ quality of life compared with simple tumor resection has not been reported. Patients with primary RPS who underwent radical resection between 2009 and 2021 were included. Patients who were alive at the last follow-up were asked to complete the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). The primary endpoint of the study was the global health (GH) score. A total of 161 patients were included, including 77 in the MVR group and 84 in the non-MVR group. When comparing EORTC scores on functional domains and symptom scales between MVR and non-MVR groups, only constipation scores differed (p = 0.011). Comparing GH scores within 6 months after surgery between the two groups, GH was better in non-MVR patients (58.3 vs. 76.4, p = 0.082). However, patients with longer postoperative intervals in the MVR group had higher scores (p < 0.001), and patients with postoperative intervals of more than one year scored similar to those in the non-MVR group (64.7 vs. 59.2, p = 0.522). As the postoperative interval increased, there was an improvement in all indicators in MVR patients, while there was no significant improvement in non-MVR patients. Aggressive surgical approaches impair quality of life within 6 months postoperatively, but the long-term quality of life is similar to that of patients undergoing simple tumor resection. This should be factored into RPS treatment decisions.
format Online
Article
Text
id pubmed-9600768
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96007682022-10-27 Does Aggressive Surgery Mean Worse Quality of Life and Functional Capacity in Retroperitoneal Sarcoma Patients?—A Retrospective Study of 161 Patients from China Zhuang, Aobo Fang, Yuan Ma, Lijie Yang, Hua Lu, Weiqi Zhou, Yuhong Zhang, Yong Tong, Hanxing Cancers (Basel) Article SIMPLE SUMMARY: The mainstay of treatment for primary retroperitoneal sarcoma is surgery. In this study, we found that aggressive surgery did not imply a poorer quality of life and functional capacity compared to a surgical strategy of simple tumor resection. This has implications for patient consultation in daily practice, the clinical decision-making of surgeons, and even for subsequent prospective clinical studies on the quality of life. ABSTRACT: The mainstay of treatment for primary retroperitoneal sarcoma (RPS) is surgery. However, whether multiple visceral resection (MVR) affects patients’ quality of life compared with simple tumor resection has not been reported. Patients with primary RPS who underwent radical resection between 2009 and 2021 were included. Patients who were alive at the last follow-up were asked to complete the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). The primary endpoint of the study was the global health (GH) score. A total of 161 patients were included, including 77 in the MVR group and 84 in the non-MVR group. When comparing EORTC scores on functional domains and symptom scales between MVR and non-MVR groups, only constipation scores differed (p = 0.011). Comparing GH scores within 6 months after surgery between the two groups, GH was better in non-MVR patients (58.3 vs. 76.4, p = 0.082). However, patients with longer postoperative intervals in the MVR group had higher scores (p < 0.001), and patients with postoperative intervals of more than one year scored similar to those in the non-MVR group (64.7 vs. 59.2, p = 0.522). As the postoperative interval increased, there was an improvement in all indicators in MVR patients, while there was no significant improvement in non-MVR patients. Aggressive surgical approaches impair quality of life within 6 months postoperatively, but the long-term quality of life is similar to that of patients undergoing simple tumor resection. This should be factored into RPS treatment decisions. MDPI 2022-10-19 /pmc/articles/PMC9600768/ /pubmed/36291911 http://dx.doi.org/10.3390/cancers14205126 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhuang, Aobo
Fang, Yuan
Ma, Lijie
Yang, Hua
Lu, Weiqi
Zhou, Yuhong
Zhang, Yong
Tong, Hanxing
Does Aggressive Surgery Mean Worse Quality of Life and Functional Capacity in Retroperitoneal Sarcoma Patients?—A Retrospective Study of 161 Patients from China
title Does Aggressive Surgery Mean Worse Quality of Life and Functional Capacity in Retroperitoneal Sarcoma Patients?—A Retrospective Study of 161 Patients from China
title_full Does Aggressive Surgery Mean Worse Quality of Life and Functional Capacity in Retroperitoneal Sarcoma Patients?—A Retrospective Study of 161 Patients from China
title_fullStr Does Aggressive Surgery Mean Worse Quality of Life and Functional Capacity in Retroperitoneal Sarcoma Patients?—A Retrospective Study of 161 Patients from China
title_full_unstemmed Does Aggressive Surgery Mean Worse Quality of Life and Functional Capacity in Retroperitoneal Sarcoma Patients?—A Retrospective Study of 161 Patients from China
title_short Does Aggressive Surgery Mean Worse Quality of Life and Functional Capacity in Retroperitoneal Sarcoma Patients?—A Retrospective Study of 161 Patients from China
title_sort does aggressive surgery mean worse quality of life and functional capacity in retroperitoneal sarcoma patients?—a retrospective study of 161 patients from china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600768/
https://www.ncbi.nlm.nih.gov/pubmed/36291911
http://dx.doi.org/10.3390/cancers14205126
work_keys_str_mv AT zhuangaobo doesaggressivesurgerymeanworsequalityoflifeandfunctionalcapacityinretroperitonealsarcomapatientsaretrospectivestudyof161patientsfromchina
AT fangyuan doesaggressivesurgerymeanworsequalityoflifeandfunctionalcapacityinretroperitonealsarcomapatientsaretrospectivestudyof161patientsfromchina
AT malijie doesaggressivesurgerymeanworsequalityoflifeandfunctionalcapacityinretroperitonealsarcomapatientsaretrospectivestudyof161patientsfromchina
AT yanghua doesaggressivesurgerymeanworsequalityoflifeandfunctionalcapacityinretroperitonealsarcomapatientsaretrospectivestudyof161patientsfromchina
AT luweiqi doesaggressivesurgerymeanworsequalityoflifeandfunctionalcapacityinretroperitonealsarcomapatientsaretrospectivestudyof161patientsfromchina
AT zhouyuhong doesaggressivesurgerymeanworsequalityoflifeandfunctionalcapacityinretroperitonealsarcomapatientsaretrospectivestudyof161patientsfromchina
AT zhangyong doesaggressivesurgerymeanworsequalityoflifeandfunctionalcapacityinretroperitonealsarcomapatientsaretrospectivestudyof161patientsfromchina
AT tonghanxing doesaggressivesurgerymeanworsequalityoflifeandfunctionalcapacityinretroperitonealsarcomapatientsaretrospectivestudyof161patientsfromchina